ABGSC Life Science Summit

Stockholm

May 30

Forward-looking statement

This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate.

A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Nykode Therapeutics | ABGSC Life Science Summit

2

Global leader in APC-targeted immunotherapy technology

NYKODE THERAPEUTICS (NYKD-OL, MKT CAP ~$700M)

Proprietary immunotherapies targeting antigens to Antigen-Presenting Cell (APC) and generating strong CD8 killer T cell responses correlated with clinical responses in solid tumors

Modular, versatile platform

  • Easily incorporate new antigens and adapt to new diseases across oncology, infectious diseases and autoimmunity

Rapidly advancing wholly owned lead asset, VB10.16, immunotherapy for HPV16+ cancers

  • Final data from phase 2 VB-C-02- unprecedented long lasting survival benefit in advanced cervical cancer
  • Potentially registrational study in advanced cervical cancer to initiate 2023
  • Dose escalation study with KEYTRUDA®1 in head and neck cancer to initiate 1H2023

Strategic partnerships to advance clinical programs and commercialize assets worldwide2

Well-capitalized with a cash position of $186m at March 31, 2023

  1. Note: KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
  2. Note: Genentech has an exclusive license to VB10.NEO. Collaboration and license to 5 programs with Regeneron. Collaboration and license with Adaptive Biotechnologies on SARS-CoV-2 T cell vaccine. Roche supplies atezolizumab; . Merck (MSD) supplies pembrolizumab

Nykode Therapeutics | ABGSC Life Science Summit

3

Nykode executive management

Experienced and international management team

MICHAEL ENGSIG

AGNETE FREDRIKSEN

MIKKEL W. PEDERSEN

KLAUS EDVARDSEN

HARALD GURVIN

Chief Executive Officer

Chief Business Officer &

Chief Scientific Officer

Chief Development Officer

Chief Financial Officer

Co-founder

Nykode Therapeutics | ABGSC Life Science Summit

4

Rich and diversified pipeline

Asset

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Rights

Oncology

VB10.16

HPV16+ cervical cancer

VB10.16

HPV16+ head and neck cancer

Off-the-shelf

Regeneron

Undisclosed

programs

Internal

Undisclosed

Melanoma, lung, bladder, renal,

VB10.NEO

head and neck cancer; locally

Individualized

advanced and metastatic tumors

VB10.NEO

Locally advanced and

metastatic tumors

Infectious Disease

1

2

3

4

4

Regeneron

Undisclosed

programs

Internal

Undisclosed

Autoimmune

3

Internal

Undisclosed

1. Wholly-owned by Nykode. Potentially registrational. Roche supplies atezolizumab; 2. Wholly-owned by Nykode. Merck (MSD) supplies pembrolizumab; 3. Collaboration with Regeneron; 4. Genentech has an exclusive license to VB10.NEO.

Nykode Therapeutics | ABGSC Life Science Summit

5

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Nykode Therapeutics AS published this content on 07 June 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 June 2023 05:29:01 UTC.